Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis

Alessandro Mantovani; Riccardo Morandin; Veronica Fiorio; Maria Giovanna Lando; Alberto Gaviraghi; Leonardo Motta; Federico Gobbi; Herbert Tilg; Christopher D Byrne; Giovanni Targher

doi:10.1111/liv.16101

Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis

Liver Int. 2024 Sep 11. doi: 10.1111/liv.16101. Online ahead of print.

Authors

Affiliations

¹ Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University of Verona, Verona, Italy.
² Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Italy.
³ Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
⁴ Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University Innsbruck, Innsbruck, Austria.
⁵ National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton, UK.
⁶ Department of Medicine, University of Verona, Verona, Italy.
⁷ Metabolic Diseases Research Unit, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella, Italy.

PMID: 39258758
DOI: 10.1111/liv.16101

Abstract

Background: Previous studies have reported an association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of serious bacterial infections. However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain. We performed a meta-analysis of observational studies to quantify the association between MASLD and serious bacterial infections requiring hospital admission.

Methods: We systematically searched PubMed, Scopus, Web of Science and Embase from database inception to 1 April 2024, using predefined keywords to identify studies examining the risk of serious bacterial infections among individuals with and without MASLD. MASLD was diagnosed using liver biopsy, imaging or International Classification of Diseases codes. Meta-analysis was performed using random-effects modelling.

Results: We identified six cross-sectional and two prospective cohort studies with aggregate data on ~26.6 million individuals. MASLD was significantly associated with higher odds of serious bacterial infections (pooled random-effects odds ratio 1.93, 95% confidence interval [CI] 1.44-2.58; I² = 93%). Meta-analysis of prospective cohort studies showed that MAFLD was associated with an increased risk of developing serious bacterial infections (pooled random-effects hazard ratio 1.80, 95% CI 1.62-2.0; I² = 89%). This risk further increased across the severity of MASLD, especially the severity of fibrosis (pooled random-effects hazard ratio 2.42, 95% CI 1.89-2.29; I² = 92%). These results remained significant after adjusting for age, sex, obesity, diabetes and other potential confounders. Sensitivity analyses did not modify these findings. The funnel plot did not reveal any significant publication bias.

Conclusions: This meta-analysis shows a significant association between MASLD and an increased risk of serious bacterial infections requiring hospital admission.

Keywords: MASLD; NAFLD; metabolic dysfunction‐associated steatotic liver disease; meta‐analysis; non‐alcoholic fatty liver disease; serious bacterial infections.